Cat. No.: HY-N0324

Cholic acid

21 Cited Publications

Avis client

Based on 21 publication(s) in Google Scholar

Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.80%
CAS No.: 81-25-4
Formule: C₂₄H₄₀O₅
Masse moléculaire:408.57

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cholic acid Chemical Structure

CAS No.: 81-25-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (21)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active^[1]^[2].

IC₅₀ & Target

Human Endogenous Metabolite

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>200 μM Compound: CA	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
CHO	EC₅₀	13.6 μM Compound: 3, CA	Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay	[PMID: 17685603]
CHO	EC₅₀	13.6 μM Compound: 5, CA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
CHO	EC₅₀	13.6 μM Compound: 4, CA	Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay	[PMID: 20014870]
COS-1	EC₅₀	>100 μM Compound: 4, CA	Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay	[PMID: 20014870]
GBM	IC₅₀	>50 μM Compound: 1a, CA, cholic acid	Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HCT-116	IC₅₀	>50 μM Compound: 1a, CA, cholic acid	Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HCT-116	IC₅₀	>200 μM Compound: CA	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HEK293	IC₅₀	>1000 μM Compound: 25	Antiproliferative activity against HEK293 cells by MTT assay Antiproliferative activity against HEK293 cells by MTT assay	[PMID: 18805690]
HEK293	IC₅₀	5.3 μM Compound: 1, CA	Agonist activity at mouse TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level Agonist activity at mouse TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level	[PMID: 20801037]
HEK293	IC₅₀	6 μM Compound: 1, CA	Agonist activity at human TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level Agonist activity at human TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level	[PMID: 20801037]
HEK-293T	EC₅₀	>150 μM Compound: CA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	>150 μM Compound: CA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HET-1A	CC₅₀	1075 μM Compound: 4, CA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-29	IC₅₀	>200 μM Compound: CA	Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
Huh-7	IC₅₀	>200 μM Compound: CA	Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
KMS-11	IC₅₀	>50 μM Compound: 1a, CA, cholic acid	Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
LoVo	IC₅₀	>200 μM Compound: CA	Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
MCF7	IC₅₀	50 μM Compound: 25	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 18805690]
MGC-803	IC₅₀	>200 μM Compound: CA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
NCI-H716	EC₅₀	13.6 μM Compound: 1, CA	Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis	[PMID: 24900463]
RKO	IC₅₀	>200 μM Compound: CA	Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SK-HEP1	IC₅₀	>200 μM Compound: CA	Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SW480	IC₅₀	>200 μM Compound: CA	Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]

In Vitro

Cholic acid (1 mg/mL, 30 min) competitively binds Na⁺/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cholic acid (1% (w/w) Cholic acid-supplemented diet; p.o.; 14 days) decreases SHP (small heterodimer partner) protein expression, potentially via the upregulation of miR142-3p. Cholic acid increases CYP2D6 expression and activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Tg-CYP2D6 adult male mice (8 weeks of age and weighing 20–25 g)^[2]
Dosage:

1% (w/w) Cholic acid-supplemented diet
Administration:

Oral, 14 days
Result:

Decreases SHP expression and increased CYP2D6 activity.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 81-25-4
Appearance Solid
Masse moléculaire 408.57
Formule C₂₄H₄₀O₅
Color White to off-white
SMILES

C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (21)

All In Vivo Efficacy StudyHistological Imaging/StainingBio/Physico-chemical AssayWBRT-PCR

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Cancer Cell

Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. [Abstract]

2024 Aug 12;42(8):1386-1400.e8. PMID: 39137727
Cell Res

Virus-induced accumulation of intracellular bile acids activates the TGR5-β-arrestin-SRC axis to enable innate antiviral immunity. [Abstract]

2019 Mar;29(3):193-205. PMID: 30651583
Adv Mater

Light-Driven Artificial Cell Micromotors for Degenerative Knee Osteoarthritis. [Abstract]

2025 Apr;37(17):e2416349. PMID: 40025988
Cell Host Microbe

Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease. [Abstract]

2025 Aug 19:S1931-3128(25)00291-4. PMID: 40848719
Cell Host Microbe

A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. [Abstract]

2024 Feb 14;32(2):191-208.e9. PMID: 38237593
J Adv Res

Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment. [Abstract]

2025 Jul:73:427-442. PMID: 39243941

Cholic acid purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jul:73:427-442. [Abstract]

The tumor-promoting effects of taurine could be reversed by bile acids (Cholic acid (245.25 mg/kg; p.o.; Once daily)) in C57 mice (n = 6).
Trends Biotechnol

Engineering Bacillus subtilis as a sustainable platform for the production of functional bile acids. [Abstract]

2026 Apr 15:S0167-7799(26)00130-7. PMID: 41991462
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Cholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Research (Wash D C)

Single-Cell RNA Transcriptomics and Multi-omics Analyses Reveal the Clinical Effects of Acupuncture on Methadone Reduction. [Abstract]

2025 Jun 24:8:0741. PMID: 40556944
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318
Cell Rep

Multilevel regulation of c-di-GMP biosynthesis by cAMP signaling increases Shigella sonnei fitness and pathogenicity in response to bile salts. [Abstract]

2025 Sep 17;44(10):116306. PMID: 40966079
Mol Neurobiol

Brain Immune Cell Infiltration and Serum Metabolomic Characteristics Reveal that Lauric Acid Promotes Immune Cell Infiltration in Brain and Streptococcus suis Meningitis in Mice. [Abstract]

2024 Nov;61(11):9302-9319. PMID: 38625620
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
Front Cell Dev Biol

Comprehensive Analysis of Quantitative Proteomics With DIA Mass Spectrometry and ceRNA Network in Intrahepatic Cholestasis of Pregnancy. [Abstract]

2022 Jul 22:10:854425. PMID: 35938169

Cholic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Jul 22:10:854425. [Abstract]

HE results of the placental explant. NC Group: normal placenta; ICP group: normal placenta was stimulated for 48 h with 100 uM Cholic acid.

Cholic acid purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Jul 22:10:854425. [Abstract]

Western blotting results and gray histogram of the placental explant. NC group: normal placenta; ICP group: the normal placenta was stimulated for 48 h with 100 uM Cholic acid.
Aquaculture

2023 Sep 18, 740123.

Cholic acid purchased from MedChemExpress. Usage Cited in: Aquaculture. 2023 Sep 18, 740123.

The results showed that dietary Cholic acid (CA, 100 mg/kg) supplementation increased the levels of T-CHO, LDL-C, and HDL-C (P < 0.05).

Cholic acid purchased from MedChemExpress. Usage Cited in: Aquaculture. 2023 Sep 18, 740123.

Cholic acid (CA, 100 mg/kg; dietary administration) significantly increased the mRNA expression levels of IL-6, IL-8, IL-1β, and iNOS in grass carp.
Microb Pathog

Lithocholic acid exerts antiviral activity against porcine epidemic diarrhea virus by enhancing TGR5-mediated type III interferon production. [Abstract]

2026 Jan:210:108187. PMID: 41242567
Drug Metab Dispos

2026 Feb 24.
J Pharm Biomed Anal

Integrating 16S rDNA sequencing analysis and targeted metabolomics to explore the mechanism of Xiexin Tang in treating atherosclerosis mice induced by high-fat diet. [Abstract]

2025 Jul 15:259:116760. PMID: 40014894
J Voice

Deoxycholic Acid Drives ATP4A-Dependent Growth and Migration of Vocal Fold Leukoplakia Epithelial Cells via TGR5/JAK2/STAT3 Signaling. [Abstract]

2025 Nov 29:S0892-1997(25)00490-4. PMID: 41320587
Transl Cancer Res

Identification of metabolic driver genes and targeted drug screening for lung adenocarcinoma metastasis at the single-cell resolution. [Abstract]

2025 Aug 31;14(8):4774-4790. PMID: 40950658

Solvant et solubilité

In Vitro:

DMSO : ≥ 50 mg/mL (122.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

0.1 M NaOH : 33.33 mg/mL (81.58 mM; ultrasonic and adjust pH to 9 with NaOH)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4476 mL

12.2378 mL

24.4756 mL

5 mM

0.4895 mL

2.4476 mL

4.8951 mL

10 mM

0.2448 mL

1.2238 mL

2.4476 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684. [Content Brief]

[2]. Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
0.1 M NaOH / DMSO	1 mM	2.4476 mL	12.2378 mL	24.4756 mL	61.1890 mL
	5 mM	0.4895 mL	2.4476 mL	4.8951 mL	12.2378 mL
	10 mM	0.2448 mL	1.2238 mL	2.4476 mL	6.1189 mL
	15 mM	0.1632 mL	0.8159 mL	1.6317 mL	4.0793 mL
	20 mM	0.1224 mL	0.6119 mL	1.2238 mL	3.0595 mL
	25 mM	0.0979 mL	0.4895 mL	0.9790 mL	2.4476 mL
	30 mM	0.0816 mL	0.4079 mL	0.8159 mL	2.0396 mL
	40 mM	0.0612 mL	0.3059 mL	0.6119 mL	1.5297 mL
	50 mM	0.0490 mL	0.2448 mL	0.4895 mL	1.2238 mL
	60 mM	0.0408 mL	0.2040 mL	0.4079 mL	1.0198 mL
	80 mM	0.0306 mL	0.1530 mL	0.3059 mL	0.7649 mL
DMSO	100 mM	0.0245 mL	0.1224 mL	0.2448 mL	0.6119 mL

Keywords

Cholic acid

21 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Cholic acid

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Food Additive Library

Food-Sourced Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Tibetan Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Bile Acids Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lipid Metabolite Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cholic acid

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Activité biologique

Chemical Information

Publications (21)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Cholic acid Related Classifications

HY-N0324 Related Classifications